Related Experiment Video

Updated: Aug 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

[Differential expression of the genes in leukemia cell apoptosis induced by TRAIL]

Yan-xin Liu1, Huan-kai Hu, De-xian Zheng

  • 1National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, CAMS and PUMC, Beijing 100005, China.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|August 9, 2003
PubMed
Abstract

Insights

Recombinant soluble tumor necrosis factor-related apoptosis inducing ligand (rsTRAIL) induced differential gene expression in leukemia cells. Five novel cDNA fragments were identified, with D1 showing potential as a tumor-specific gene.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Apoptosis

Context:

  • Leukemia is a significant health concern.
  • Understanding gene expression in apoptosis is crucial for cancer therapy.
  • Recombinant soluble tumor necrosis factor-related apoptosis inducing ligand (rsTRAIL) is a potential therapeutic agent.

Purpose:

  • To identify genes differentially expressed during TRAIL-induced apoptosis in leukemia cells.
  • To characterize the expression patterns of these genes.

Summary:

  • Suppression subtractive hybridization (SSH) and PCR identified six differentially expressed cDNA fragments in TRAIL-treated Jurkat cells.
  • Five novel cDNA fragments (A14, X1, D1, A23, C5) were discovered and registered in GenBank.
  • Gene D1 exhibited higher expression in Jurkat and MCF-7 cells compared to other cancer cell lines.

Impact:

  • Discovery of novel genes involved in leukemia apoptosis.
  • Identification of D1 as a potential tumor-specific gene for further investigation.
  • Provides insights into molecular mechanisms of TRAIL-induced apoptosis in cancer.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...